Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development

ABSTRACTDeveloping software tools that leverage biological data sets to accelerate drug discovery is an important aspect of bioinformatic research. Here, we present a novel example: a web application called Rocket-miR that applies an existing bioinformatic algorithm (IntaRNA) to predict cross-specie...

Full description

Bibliographic Details
Main Authors: Samuel L. Neff, Thomas H. Hampton, Katja Koeppen, Sharanya Sarkar, Casey J. Latario, Benjamin D. Ross, Bruce A. Stanton
Format: Article
Language:English
Published: American Society for Microbiology 2023-12-01
Series:mSystems
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/msystems.00653-23
_version_ 1797383247367241728
author Samuel L. Neff
Thomas H. Hampton
Katja Koeppen
Sharanya Sarkar
Casey J. Latario
Benjamin D. Ross
Bruce A. Stanton
author_facet Samuel L. Neff
Thomas H. Hampton
Katja Koeppen
Sharanya Sarkar
Casey J. Latario
Benjamin D. Ross
Bruce A. Stanton
author_sort Samuel L. Neff
collection DOAJ
description ABSTRACTDeveloping software tools that leverage biological data sets to accelerate drug discovery is an important aspect of bioinformatic research. Here, we present a novel example: a web application called Rocket-miR that applies an existing bioinformatic algorithm (IntaRNA) to predict cross-species miRNA-mRNA interactions and identify human miRNAs with potential antimicrobial activity against antibiotic-resistant bacterial infections. Rocket-miR is the logical extension of our prior finding that human miRNA let-7b-5p impairs the ability of the ubiquitous opportunistic pathogen Pseudomonas aeruginosa to form biofilms and resist the bactericidal effect of β-lactam antibiotics. Rocket-miR’s point and click interface enables researchers without programming expertise to predict additional human-miRNA-pathogen interactions. Identified miRNAs can be developed into novel antimicrobials effective against the 24 clinically relevant pathogens, implicated in diseases of the lung, gut, and other organs, that are included in the application. The paper incorporates three case studies contributed by microbiologists that study human pathogens to demonstrate the usefulness and usability of the application. Rocket-miR is accessible at the following link: http://scangeo.dartmouth.edu/RocketmiR/.IMPORTANCEAntimicrobial-resistant infections contribute to millions of deaths worldwide every year. In particular, the group of bacteria collectively known as ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application’s target audience are microbiologists that have the laboratory resources to test the application’s predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.
first_indexed 2024-03-08T21:17:06Z
format Article
id doaj.art-38af883ac4f94636bc3aa24c3f8bf9e5
institution Directory Open Access Journal
issn 2379-5077
language English
last_indexed 2024-03-08T21:17:06Z
publishDate 2023-12-01
publisher American Society for Microbiology
record_format Article
series mSystems
spelling doaj.art-38af883ac4f94636bc3aa24c3f8bf9e52023-12-21T14:02:34ZengAmerican Society for MicrobiologymSystems2379-50772023-12-018610.1128/msystems.00653-23Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug developmentSamuel L. Neff0Thomas H. Hampton1Katja Koeppen2Sharanya Sarkar3Casey J. Latario4Benjamin D. Ross5Bruce A. Stanton6Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USADepartment of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USAABSTRACTDeveloping software tools that leverage biological data sets to accelerate drug discovery is an important aspect of bioinformatic research. Here, we present a novel example: a web application called Rocket-miR that applies an existing bioinformatic algorithm (IntaRNA) to predict cross-species miRNA-mRNA interactions and identify human miRNAs with potential antimicrobial activity against antibiotic-resistant bacterial infections. Rocket-miR is the logical extension of our prior finding that human miRNA let-7b-5p impairs the ability of the ubiquitous opportunistic pathogen Pseudomonas aeruginosa to form biofilms and resist the bactericidal effect of β-lactam antibiotics. Rocket-miR’s point and click interface enables researchers without programming expertise to predict additional human-miRNA-pathogen interactions. Identified miRNAs can be developed into novel antimicrobials effective against the 24 clinically relevant pathogens, implicated in diseases of the lung, gut, and other organs, that are included in the application. The paper incorporates three case studies contributed by microbiologists that study human pathogens to demonstrate the usefulness and usability of the application. Rocket-miR is accessible at the following link: http://scangeo.dartmouth.edu/RocketmiR/.IMPORTANCEAntimicrobial-resistant infections contribute to millions of deaths worldwide every year. In particular, the group of bacteria collectively known as ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application’s target audience are microbiologists that have the laboratory resources to test the application’s predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.https://journals.asm.org/doi/10.1128/msystems.00653-23cystic fibrosisbioinformaticsmiRNACF pathogensantimicrobial agentshost-pathogen interactions
spellingShingle Samuel L. Neff
Thomas H. Hampton
Katja Koeppen
Sharanya Sarkar
Casey J. Latario
Benjamin D. Ross
Bruce A. Stanton
Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
mSystems
cystic fibrosis
bioinformatics
miRNA
CF pathogens
antimicrobial agents
host-pathogen interactions
title Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
title_full Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
title_fullStr Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
title_full_unstemmed Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
title_short Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development
title_sort rocket mir a translational launchpad for mirna based antimicrobial drug development
topic cystic fibrosis
bioinformatics
miRNA
CF pathogens
antimicrobial agents
host-pathogen interactions
url https://journals.asm.org/doi/10.1128/msystems.00653-23
work_keys_str_mv AT samuellneff rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT thomashhampton rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT katjakoeppen rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT sharanyasarkar rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT caseyjlatario rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT benjamindross rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment
AT bruceastanton rocketmiratranslationallaunchpadformirnabasedantimicrobialdrugdevelopment